In 1996, it was discovered that the anti-CTLA-4 antibody (Ab) demonstrated potent antitumor effects with its administration in tumor-transplanted mice, leading to the rejection of the tumor, even when anti-CTLA4 was given a week after initial transplantation of the tumor [22]. Here, CTLA4 is linked to neoplasm.